CPC A61K 39/39 (2013.01) [A61K 39/0011 (2013.01); A61K 39/00117 (2018.08); A61K 39/001104 (2018.08); A61K 39/001106 (2018.08); A61K 39/001109 (2018.08); A61K 39/001135 (2018.08); A61K 39/001151 (2018.08); A61K 39/001153 (2018.08); A61K 39/001156 (2018.08); A61K 39/001157 (2018.08); A61K 39/001164 (2018.08); A61K 39/001168 (2018.08); A61K 39/001182 (2018.08); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/001191 (2018.08); A61K 39/001192 (2018.08); A61K 39/001193 (2018.08); A61K 39/001194 (2018.08); A61K 39/001195 (2018.08); A61K 39/12 (2013.01); A61K 39/145 (2013.01); A61K 39/205 (2013.01); A61K 39/29 (2013.01); A61K 39/35 (2013.01); A61K 47/645 (2017.08); A61K 47/646 (2017.08); A61K 48/0041 (2013.01); C12N 7/00 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/572 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6093 (2013.01); C12N 2710/20034 (2013.01); C12N 2710/20071 (2013.01); C12N 2730/10134 (2013.01); C12N 2730/10171 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16171 (2013.01); C12N 2760/20134 (2013.01); C12N 2760/20171 (2013.01); Y02A 50/30 (2018.01)] | 20 Claims |
1. A method of inducing an immune response to an antigen, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising:
(A) a polymeric carrier cargo complex, comprising:
a) a polymeric carrier comprising disulfide-crosslinked cationic peptides, as a carrier; and
b) at least one immunostimulatory RNA (isRNA) molecule as a cargo,
wherein the cationic components and the isRNA molecule of the polymeric carrier cargo complex are provided in a nitrogen to phosphor atoms (N/P) ratio in the range of 0.1-0.9,
and
(B) at least one protein or peptide antigen that is selected from the group consisting of:
a) an antigen from a pathogen associated with infectious disease;
b) an antigen associated with allergy or allergic disease;
c) an antigen associated with autoimmune disease; and
d) an antigen associated with a cancer or tumour disease,
wherein said pharmaceutical composition lacks an mRNA component,
wherein the cationic peptides each comprise a sequence selected from the group consisting of CR7-20C (SEQ ID NOs: 1-14),
wherein the at least one protein or peptide antigen is a separate component of the pharmaceutical composition from the polymeric carrier cargo complex.
|